A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application

ConclusionsPatients treated with palbociclib, on average, reported consistently low levels of pain and fatigue as well as good QOL and overall health that remained stable throughout the first 6  months of treatment regardless of episodes of neutropenia.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research